LONDON, June 16, 2016 (GLOBE NEWSWIRE) -- LivaNova PLC (the " Company " or " LivaNova ") announces that, on 15 June 2016, the following persons discharging managerial responsibilities (" PDMRs ") have received, or will receive, the following amount in cash in lieu of ordinary shares (" Shares ") on the vesting of the following restricted stock units (" RSUs ") on the basis of US$ 48.485 per Share, which was the closing price for the Shares on 14 June 2016, as set out below.
Name of PDMR
|Value of RSUs (US$)||Number of Shares subject to the RSUs||
Amount received on settlement of RSUs
|Daniel J. Moore||156,164||2,233||108,267.01|
|Alfred J. Novak||84,603||1,209||58,618.37|
|Dr. Arthur L. Rosenthal||84,603||1,209||58,618.37|
|Dr. Sharon O'Kane||84,603||1,209||58,618.37|
This announcement is made pursuant to Disclosure and Transparency Rule 3.1.4R.
LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of the UK's Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol "LIVN".
For more information, please visit www.livanova.com, or contact:
Investor Relations and Media
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332